LIGAND PHARMACEUTICALS INC (LGND) — Institutional Holders, Q2 2026 (page 5)

418 institutional investment managers reported a LGND position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $7.1B. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 401 to 418. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.

LGND 13F holders ranked 401–418 of 418

Institutional investors reporting a position in LIGAND PHARMACEUTICALS INC on SEC Form 13F-HR for Q2 2026, ranked by reported value.
InstitutionValueQoQ
Prestige Wealth Management Group#401 · 3 sh$949.00+50.0%
Rialto Wealth Management#402 · 3 sh$949.00+200.0%
GILPIN WEALTH MANAGEMENT#403 · 3 sh$949.000.0%
ZIONS BANCORPORATION, NATIONAL ASSOCIATION#404 · 3 sh$948.000.0%
Plante Moran Financial Advisors#405 · 3 sh$948.00New
Ronald Blue#406 · 3 sh$948.000.0%
1620 INVESTMENT ADVISORS#407 · 3 sh$948.00New
Ankerstar Wealth#408 · 3 sh$948.000.0%
Mascoma Wealth Management#409 · 2 sh$632.00New
Creative Capital Management Investments#410 · 2 sh$632.00New
GHP Investment Advisors#411 · 1 sh$317.000.0%
Abound Wealth Management#412 · 1 sh$317.000.0%
Clearstead Advisors#413 · 1 sh$317.00New
Davis Capital Management#414 · 1 sh$316.00New
Inspire Investing#415 · 1 sh$199.00-99.9%
Evolution Advisers#416 · 2 sh$0.00New
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM#417 · 22,053 sh—-7.3%
Context Capital Management#418 · 46,000 sh—New

Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.